Primary Liver Cancers
Conditions
Brief summary
To fill in the Brief Summary field, you need to provide clear, easy-to-understand information about the study for patients, families, and healthcare providers. Here's a suggested summary: This study compares the dosimetric features and clinical effects of body gamma knife and VMAT radiotherapy for locally advanced primary liver cancer. We retrospectively analyze 20 patients from Chifeng Tumor Hospital who cannot or refuse surgery. For each patient, we will develop both body gamma knife and VMAT radiotherapy plans. Then, we'll compare the dose distribution in the tumor target (including conformity index and homogeneity index) and the radiation exposure to organs at risk (such as the spinal cord, stomach, and liver). The goal is to find out which radiotherapy approach is more beneficial, so patients, families, and healthcare teams can better understand how this research supports treatment decisions.
Interventions
None listed
Sponsors
Chifeng Tumor Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Aged 18-75 years. * Clinically or pathologically confirmed primary liver cancer; unsuitable for or - refusing surgery, with single tumor diameter ≤5 cm and ≤5 nodules. * ECOG PS score 0-1. * Liver function: Child-Pugh grade A or B. * Prothrombin time (PT) \< 4 seconds above the normal control range. * No hepatic encephalopathy or moderate to large ascites. * Renal and cardiopulmonary function basically normal. * Gastroscopy findings: no severe esophageal varices or active peptic ulcer. * Hemoglobin ≥90 g/L, WBC ≥3.0×10⁹/L, neutrophil ≥1.5×10⁹/L, platelet ≥40×10⁹/L. * No obvious cachexia; life expectancy \> 3 months. * Not pregnant; no HIV or syphilis infection. * Able to understand the study and sign informed consent.
Exclusion criteria
* History of portal hypertension, esophageal variceal bleeding, or related conditions. * History of anti-RHCC treatment or spontaneous tumor rupture. * Postoperative pathology indicates metastatic cancer or other primary cancers. * Cerebrovascular accident within 6 months before enrollment. * Severe lung disease; serum creatinine \> 1.25×the upper normal limit. * Poorly controlled acute or active infection; severe mental illness. * Suspected systemic or local lymphadenopathy on imaging. * Pregnant or lactating women; presence of other serious underlying diseases. * Currently participating in other clinical trials; refusal to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Conformity Index Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer | Within 1 month after completion of radiotherapy planning | Compare the conformity index (a dosimetric measure of how well radiation conforms to the target volume) between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gradient Index Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer | Within 1 month after completion of radiotherapy planning | Compare the gradient index (a dosimetric measure of dose fall-off outside the target volume) between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer. |
| Homogeneity Index Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer | Within 1 month after completion of radiotherapy planning | Compare the homogeneity index (a dosimetric measure of dose uniformity within the target volume) between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer. |
| Liver V20 Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer | Within 1 month after completion of radiotherapy planning | Compare the volume of liver receiving 20 Gy (V20) between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer. |
| Liver Mean Dose (Dmean) Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer | Within 1 month after completion of radiotherapy planning | Compare the mean dose (Dmean) to the liver between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer. |
| Liver V5 Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer | Within 1 month after completion of radiotherapy planning | Compare the volume of liver receiving 5 Gy (V5) between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer. |
Countries
China
Contacts
Primary ContactJiarui zhang
Outcome results
None listed